[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples